Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians

Imagem de Miniatura
Arquivos
art_MISKOWIAK_Assessing_and_addressing_cognitive_impairment_in_bipolar_disorder_2018.PDF (484.66 KB)
Citações na Scopus
117
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
MISKOWIAK, K. W.
BURDICK, K. E.
MARTINEZ-ARAN, A.
BONNIN, C. M.
BOWIE, C. R.
CARVALHO, A. F.
GALLAGHER, P.
LOPEZ-JARAMILLO, C.
SUMIYOSHI, T.
Citação
BIPOLAR DISORDERS, v.20, n.3, p.184-194, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesCognition is a new treatment target to aid functional recovery and enhance quality of life for patients with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force aimed to develop consensus-based clinical recommendations on whether, when and how to assess and address cognitive impairment. MethodsThe task force, consisting of 19 international experts from nine countries, discussed the challenges and recommendations in a face-to-face meeting, telephone conference call and email exchanges. Consensus-based recommendations were achieved through these exchanges with no need for formal consensus methods. ResultsThe identified questions were: (I) Should cognitive screening assessments be routinely conducted in clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief, easy-to-administer tools such as the Screen for Cognitive Impairment in Psychiatry and Cognitive Complaints in Bipolar Disorder Rating Assessment, and (III) evaluate the impact of medication and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited evidence for current evidence-based treatments but intense research efforts are underway to identify new pharmacological and/or psychological cognition treatments. ConclusionsThis task force paper provides the first consensus-based recommendations for clinicians on whether, when, and how to assess and address cognition, which may aid patients' functional recovery and improve their quality of life.
Palavras-chave
bipolar disorder, cognitive impairment, neuropsychological, recommendations, screening
URI
https://observatorio.fm.usp.br/handle/OPI/27043
Referências
  1. Bonnin CM, 2016, BRIT J PSYCHIAT, V208, P87, DOI 10.1192/bjp.bp.114.162123
  2. Bonnin CM, 2016, PSYCHOL MED, V46, P291, DOI 10.1017/S0033291715001713
  3. Bonnin CM, 2010, J AFFECT DISORDERS, V121, P156, DOI 10.1016/j.jad.2009.05.014
  4. Bourne C, 2013, ACTA PSYCHIAT SCAND, V128, P149, DOI 10.1111/acps.12133
  5. Bowie CR, 2017, PSYCHIATR REHABIL J, V40, P53, DOI 10.1037/prj0000189
  6. Breitborde Nicholas Jk, 2014, BMC Psychol, V2, P41, DOI 10.1186/s40359-014-0041-4
  7. Burdick KE, 2014, PSYCHOL MED, V44, P3083, DOI 10.1017/S0033291714000439
  8. Burdick KE, 2005, PSYCHIAT RES, V136, P43, DOI 10.1016/j.psychres.2004.12.009
  9. Chen MH, 2015, J AM MED DIR ASSOC, V16, P504, DOI 10.1016/j.jamda.2015.01.084
  10. da Silva J, 2013, BRIT J PSYCHIAT, V202, P177, DOI 10.1192/bjp.bp.111.101931
  11. Decker L, 2017, EDORIUM J DISABILITY, V3, P69
  12. Deckersbach T, 2010, CNS NEUROSCI THER, V16, P298, DOI 10.1111/j.1755-5949.2009.00110.x
  13. Demant KM, 2015, PSYCHIAT RES, V229, P565, DOI 10.1016/j.psychres.2015.05.022
  14. Demant KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127955
  15. Depp CA, 2012, BIPOLAR DISORD, V14, P217, DOI 10.1111/j.1399-5618.2012.01011.x
  16. Duff K, 2012, ARCH CLIN NEUROPSYCH, V27, P248, DOI 10.1093/arclin/acr120
  17. Forcada I, 2015, EUR NEUROPSYCHOPHARM, V25, P214, DOI 10.1016/j.euroneuro.2014.07.018
  18. Glahn DC, 2006, J AFFECT DISORDERS, V92, P309, DOI 10.1016/j.jad.2006.01.025
  19. Gomes BC, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1896-5
  20. Grande I, 2017, J AFFECT DISORDERS, V208, P621, DOI 10.1016/j.jad.2016.10.012
  21. Grande I, 2016, LANCET, V388, P869
  22. Gualtieri CT, 2008, PROG NEURO-PSYCHOPH, V32, P962, DOI 10.1016/j.pnpbp.2007.12.030
  23. Harada CN, 2013, CLIN GERIATR MED, V29, P737, DOI 10.1016/j.cger.2013.07.002
  24. Huxley N, 2007, BIPOLAR DISORD, V9, P183, DOI 10.1111/j.1399-5618.2007.00430.x
  25. Jensen JH, 2016, J AFFECT DISORDERS, V205, P378, DOI 10.1016/j.jad.2016.08.018
  26. Jensen JH, 2015, J AFFECT DISORDERS, V187, P10, DOI 10.1016/j.jad.2015.07.039
  27. Kaser Muzaffer, 2017, Biol Psychiatry Cogn Neurosci Neuroimaging, V2, P115, DOI 10.1016/j.bpsc.2016.11.009
  28. Kogan JN, 2004, BIPOLAR DISORD, V6, P460, DOI 10.1111/j.1399-5618.2004.00158.x
  29. Kupfer DJ, 2002, J CLIN PSYCHIAT, V63, P120, DOI 10.4088/JCP.v63n0206
  30. KUYKEN W, 1995, SOC SCI MED, V41, P1403
  31. Lewandowski KE, 2017, J CLIN PSYCHIAT, V78, pE1242, DOI 10.4088/JCP.17m11476
  32. Lewandowski KE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1275-7
  33. Li YL, 2016, ARCH CLIN NEUROPSYCH, V31, P365, DOI 10.1093/arclin/acw017
  34. Mackala SA, 2014, J AFFECT DISORDERS, V168, P119, DOI 10.1016/j.jad.2014.06.045
  35. Mago R, 2014, HARVARD REV PSYCHIAT, V22, P363, DOI 10.1097/HRP.0000000000000017
  36. Malhi GS, 2016, BIPOLAR DISORD, V18, P102, DOI 10.1111/bdi.12375
  37. Martinez-Aran A, 2007, BIPOLAR DISORD, V9, P103, DOI 10.1111/j.1399-5618.2007.00327.x
  38. Marwaha S, 2013, ACTA PSYCHIAT SCAND, V128, P179, DOI 10.1111/acps.12087
  39. McIntyre R. S., 2016, INT J NEUROPSYCHOPH, V19, P1
  40. Meusel LAC, 2013, PSYCHIAT RES-NEUROIM, V214, P142, DOI 10.1016/j.pscychresns.2013.06.007
  41. Miskowiak KW, 2017, BIPOLAR DISORD, V19, P614, DOI 10.1111/bdi.12534
  42. Miskowiak KW, 2016, EUR NEUROPSYCHOPHARM, V26, P1845, DOI 10.1016/j.euroneuro.2016.09.641
  43. Miskowiak KW, 2016, ACTA PSYCHIAT SCAND, V134, P511, DOI 10.1111/acps.12649
  44. Miskowiak KW, 2014, J CLIN PSYCHIAT, V75, P1347, DOI 10.4088/JCP.13m08839
  45. Miskowiak KW, 2014, NEUROPSYCHOPHARMACOL, V39, P1399, DOI 10.1038/npp.2013.335
  46. Naismith SL, 2010, J AFFECT DISORDERS, V121, P258, DOI 10.1016/j.jad.2009.06.028
  47. Ott C, 2017, TRIALS IN PRESS
  48. Ott CV, 2016, EUR NEUROPSYCHOPHARM, V26, P1264, DOI 10.1016/j.euroneuro.2016.05.009
  49. Preiss M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00108
  50. Purdon S, 2005, SCREEN COGNITIVE IMP
  51. Rej S, 2018, BIPOLAR DISORD, V20, P359, DOI 10.1111/bdi.12566
  52. Roebuck-Spencer TM, 2017, ARCH CLIN NEUROPSYCH, V32, P491, DOI 10.1093/arclin/acx021
  53. Rojo E, 2010, SCHIZOPHR RES, V116, P243, DOI 10.1016/j.schres.2009.08.005
  54. Rosa AR, 2013, J AFFECT DISORDERS, V150, P29, DOI 10.1016/j.jad.2013.02.022
  55. Smith J, 2017, MOL PSYCHIATR, V2017, P1
  56. Sole B, 2016, BIPOLAR DISORD, V18, P288, DOI 10.1111/bdi.12385
  57. Stern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015
  58. Strawbridge R, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1472-4
  59. Svendsen AM, 2012, NORD J PSYCHIAT, V66, P248, DOI 10.3109/08039488.2011.626870
  60. Torrent C, 2013, AM J PSYCHIAT, V170, P852, DOI 10.1176/appi.ajp.2012.12070971
  61. Torrent Carla, 2012, J Clin Psychiatry, V73, pe899, DOI 10.4088/JCP.11m07471
  62. Toyoshima K, 2017, PSYCHIAT RES, V254, P85, DOI 10.1016/j.psychres.2017.04.043
  63. Tse S, 2014, BIPOLAR DISORD, V16, P217, DOI 10.1111/bdi.12148
  64. Van Camp LSC, 2016, COGN NEUROPSYCHIATRY, V21, P130, DOI 10.1080/13546805.2015.1137214
  65. Veeh J, 2017, INT J BIPOLAR DISORD, V5, DOI 10.1186/s40345-017-0079-3
  66. Vieta E, 2016, WORLD PSYCHIATRY, V15, P288, DOI 10.1002/wps.20351
  67. Watson S, 2012, BIOL PSYCHIAT, V72, P943, DOI 10.1016/j.biopsych.2012.05.029
  68. Xiao L, 2015, J AFFECT DISORDERS, V173, P226, DOI 10.1016/j.jad.2014.11.011
  69. Yatham LN, 2017, LANCET PSYCHIAT, V4, P208, DOI 10.1016/S2215-0366(17)30046-9
  70. Yatham LN, 2010, BIPOLAR DISORD, V12, P351, DOI 10.1111/j.1399-5618.2010.00830.x
  71. Yen CF, 2008, COMPR PSYCHIAT, V49, P335, DOI 10.1016/j.comppsych.2007.12.006
  72. Young AH, 2004, NEUROPSYCHOPHARMACOL, V29, P1538, DOI 10.1038/sj.npp.1300471

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21